Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE 15 Jul 2019
New fast-track appraisal a boon for companies. AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its ... AbbVie welcomed NICE’s decision, and said it

Alnylam gains key NICE approval for Onpattro

Alnylam gains key NICE approval for Onpattro 10 Jul 2019
Important milestone for company's first product. NICE has reversed an earlier decision to reject Alnylam’s Onpattro, helping it compete with rival treatment Tegsedi (inotersen). ... However NICE’s initial reservations had been about just how

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo 5 Jul 2019
The go-ahead from NICE came just a day after the European Commission gave the drug a conditional approval in adults with CSCC whose cancer cannot be treated effectively with surgery ... NICE backing bodes well for other reimbursement decisions in Europe,

AstraZenca to appeal NICE rejection of Tagrisso

AstraZenca to appeal NICE rejection of Tagrisso 5 Jul 2019
For AstraZeneca, NICE’s decision is part of a wider issue with methodologies. ... It is time for a comprehensive review of how NICE values innovative medicines, concluded Soriot.

After discount row, NICE finally says yes to first line Revlimid

After discount row, NICE finally says yes to first line Revlimid 17 May 2019
In a second piece of final draft guidance published today, NICE has also recommended Revlimid as a second line therapy with dexamethasone. ... The new decision by NICE now means that those patients have an effective alternative.”.

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Infographics